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Phenotypic characteristics of members of a melanoma prone kindred with a V126D CDKN2A gene mutation were
monitored over approximately 15 y. Thirty-eight previously studied subjects were recruited. Participants underwent
a complete skin examination by the same dermatologist who examined them initially. The size and location of all
nevi were recorded on a body map diagram. Total nevus number (TNN) and total nevus density (TND) were de-
termined. CDKN2A sequencing veriﬁed 13 mutation carriers and 16 non-carriers. Nine participants were spouse
controls without a history of melanoma and did not carry a CDKN2A mutation. Mutation carriers demonstrated a
greater mean TNN and TND at initial and follow-up examinations compared with non-carriers and continued to
develop nevi rather than show nevus regression seen in non-carriers and spouse controls. Non-carriers showed an
intermediate nevus phenotype between mutation carriers and spouse controls. Four of the 13 mutation carriers and
one non-carrier have developed invasive melanoma. Over a 15-y interval, TNN and TND were increased in mutation
carriers compared with non-carriers and spouse controls. Continued accumulation of nevi in mutation carriers
supports a nevogenic role for this CDKN2A mutation. An intermediate nevus phenotype in non-carrier family
members suggests the presence of additional modiﬁer genes.
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Both genetic and environmental factors influence the de-
velopment of melanoma and cutaneous nevi but the great-
est risk factor for development of cutaneous melanoma is
being a member of a melanoma-prone family (Goldstein and
Tucker, 1995). Recognized risk factors include personal
history of melanoma (Tucker et al, 1985), multiple and atyp-
ical nevi (moles) (Newton et al, 1993; Grulich et al, 1996;
Tucker et al, 1997), red hair, freckling, history of blistering
sunburns, blue eyes (Marrett et al, 1992; Bliss et al, 1995),
and Fitzpatrick type I skin (Marrett et al, 1992) (reviewed in
Kefford et al, 1999). With the exception of a single long-term
follow-up study of individual melanocytic lesions (Tucker
et al, 2002), the natural history of nevus number and density
in melanoma kindreds is unknown.
In the late 1980s and early 1990s, we recruited members
of melanoma prone families for phenotypic and genotypic
studies that culminated in the identification of a melanoma-
susceptibility locus (Cannon-Albright et al, 1992), later iden-
tified as CDKN2A (p16) (Kamb et al, 1994), an integral
member of the retinoblastoma cell cycle regulation pathway
(Piepkorn, 2000). Confirmation of the importance of this
tumor suppressor gene in familial melanoma followed and
CDKN2A mutations have been discovered in 20–40% of
melanoma kindreds (Piepkorn, 2000).
Individuals inheriting a CDKN2A mutation have an in-
creased risk of melanoma (Cannon-Albright et al, 1994;
Goldstein and Tucker, 1995) and an increased number of
nevi (Cannon-Albright et al, 1994; Zhu et al, 1999; Bishop
et al, 2000). This suggests that CDKN2A, in addition to
conferring melanoma susceptibility, may participate in ne-
vus development. But correlation of the number of nevi with
the genotypic status is problematic because of considera-
ble phenotypic overlap between CDKN2A mutation carriers
and non-carriers (Bishop et al, 2000). One possible expla-
nation for this overlap is the co-inheritance of additional
genes involved in nevus development. This possibility is
supported by the observation that increased numbers of
nevi seen in the absence of germline CDKN2A mutations
are an independent risk factor for melanoma (Grulich et al,
1996; Kefford et al, 1999). Defining the natural history of
nevus development in melanoma kindreds is an important
step in understanding the relationship between CDKN2A
mutations and other undiscovered modifier genes.
Here we report longitudinal phenotypic observations of
38 previously examined Utah melanoma kindred members
and spouse control subjects over an average interval of
15 y. This kindred was instrumental in establishing CDKN2A
as a major melanoma susceptibility gene (Cannon-Albright
et al, 1992) and carries a well-characterized CDKN2A gene
mutation, V126D, that co-segregates with melanoma sus-
ceptibility (Kamb et al, 1994). The aim of this longitudinalAbbreviations: TND, total nevus density; TNN, total nevus number
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investigation was to evaluate the effect of a single point
mutation in CDKN2A on the nevus phenotype and the de-
velopment of melanoma.
Results
Twenty-nine kindred members and nine spouse control
subjects were re-examined. The mean follow-up period was
15.8, 15.7, and 14.7 y for the mutation carrier, non-carrier,
and spouse control subjects, respectively. Thirteen were
heterozygous for the 377 T ! A mutation and 25 were non-
carriers, including nine spouse control subjects. None of the
subjects examined had additional promoter or coding re-
gion mutations of CDKN2A. There were no mutations in the
ARF coding region. The Utah Population Database, which
links multi-generation pedigree records of members of the
Church of Jesus Christ of Latter-day Saints to Utah Cancer
Registry data, was queried to determine if any of the spouse
control subjects were members of other known Utah me-
lanoma kindreds or had a personal or family history of me-
lanoma. No association was identified. Demographic data
are summarized in Table S1.
The goal of data collection was to evaluate the major risk
factors for melanoma in the context of an individual’s
CDKN2A mutation status. The following risk factors were
assessed: total nevus number (TNN) and total nevus density
(TND), constitutional phenotypic characteristics (hair color,
eye color, freckling, skin type, and natural skin pigmenta-
tion), environmental factors (including markers of chronic
sun exposure and self-reported sunburn history) and per-
sonal history of melanoma (Table I).
Mutation carriers have significantly more nevi than non-
carriers and continue to develop additional nevi The
mean and standard deviation of TNN and TND for all gen-
otype groups are shown in Table S1. Mutation carriers
demonstrated significantly larger TNN and TND at the first
examination than the non-carrier subjects, confirming
Figure 1
Mutation carriers developed more nevi (A) and have a larger TND
(B) that increased over the follow-up interval. Box-and-whiskers plot
representing median (horizontal line within box), upper quartile, lower
quartile, and range of values for TNN and TND by carrier group. I, initial
examination, F/U, follow-up examination.
Figure2
Mutation carriers demonstrate a constant increase in TNN with
age. Scatterplot of subject age at initial and follow-up examinations
versus TNN. As can be seen, the mutation carriers (A) show an increase
in TNN at a constant rate with age, whereas the non-carrier (B) and
spouse control subjects (C) tend to decrease TNN with age (best fitting
line––second-order polynomial).
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previous findings (Cannon-Albright et al, 1994). Notably, the
differences between these genotypic groups were magni-
fied over the follow-up interval, with mutation carriers con-
tinuing to develop nevi at an average of 1.83  1.66 nevi per
y, (95% CI 0.83–2.84), whereas both parameters tended
to decrease in non-carriers and spouse control subjects.
The striking phenotypic differences over the follow-up in-
terval among all genotypic groups are shown in Figs 1 and
2. Mutation carriers had significantly more clinically atypical
nevi (average 10  8) than non-carriers (average 2  2,
p¼0.0005) or spouse controls (1  2, p¼ 0.0004).
TNN was stratified into nevi o4 mm, 4–5 mm, and 45
mm revealing that mutation carriers increased the number
of nevi in all three size categories over the follow-up interval.
A significant difference in the size distribution of nevi was
not identified in non-carrier or spouse control subjects over
time (Fig 3). At the initial examination, mutation carriers had
a significantly larger number of nevi 46 mm compared with
non-carriers (p¼0.03) or spouse control subjects (p¼ 0.05).
At follow-up, mutation carriers showed significantly more
nevi in all size groups as compared with non-carriers
(pp0.03) or spouse control subjects (pp0.04). A significant
difference was not identified between non-carriers or
spouse controls in any nevus size category in the initial or
follow-up examination.
Non-carriers show an intermediate nevus pheno-
type Spouse control subjects, on average, were older than
non-carriers because they were married at the initial exam-
ination. After adjusting for the age difference, non-carriers
appear to have an intermediate nevus phenotype between
mutation carriers and spouse control subjects. Although
non-carriers have a larger TNN and TND than spouse con-
trols, the change in these parameters over the follow-up
interval is similar (Figs 1 and 2).
Nevus phenotype in CDKN2A family members is varia-
ble Nevus phenotype varied considerably within genotypic
groups, as reflected by the standard deviation for TNN and
TND. The standard deviation was greatest in the mutation
carrier group, followed by the non-carrier group, and was
least in the spouse control group (Table S1 and Fig 4). Fur-
thermore, the mutation carrier and non-carrier groups can
be subdivided into those individuals that increased the
TNN/TND, those that did not change, and those that de-
creased these parameters over the follow-up interval. These
data support the possible existence of a modifying ne-
vogenic gene in this kindred that could account for the
Figure 3
Mutation carriers show an increased number of nevi in all three
size categories. As can be seen, mutation carriers have increased
numbers of small, intermediate, and larger nevi over time, whereas
non-carriers and spouse control subjects show no significant change
over the follow-up interval.
Figure4
Subjects in all genotypic groups show variability in TNN and TND
over the follow-up interval. Each point on these scatterplot diagrams
represents the difference in TNN or TND (follow-up valueinitial value)
for each participant over the follow-up period. As can be seen, there is
significant variability in nevus development over time; subjects dem-
onstrate either an increase, a decrease, or similar numbers of counts.
These data show that the variability in TNN and TND increases from the
spouse control to mutation carrier group, suggesting the possibility of
co-inheritance of a nevogenic modifier gene in this kindred.
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intermediate nevus phenotype in non-carrier subjects and
accentuate further the difference in nevus development in
carrier subjects.
Constitutional phenotypic characteristics and environ-
mental factors Other investigators have demonstrated both
genetic and environmental components influencing the de-
velopment of nevi and melanoma in CDKN2A melanoma-
prone families (Meyer et al, 1992; Cannon-Albright et al,
1994; Goldstein et al, 1998; Bishop et al, 2000, 2002). Be-
cause nevus development has been associated with consti-
tutional phenotype (light hair, eye color, Fitzpatrick skin type)
(Green et al, 1995) as well as environmental factors, including
acute (Richard et al, 1993; Bataille et al, 1998) and chronic
sun exposure (Richard et al, 1993; Wachsmuth et al, 2001),
we sought to determine if differences in these parameters
could partially explain the dramatic phenotypic differences
observed among the genotypic groups. Presence of red hair
or light-colored eyes was not significantly associated with
increased number of nevi at the initial or follow-up examina-
tion (red hair: p¼0.17 for TNN at first visit; p¼ 0.52 for TNN
at follow-up; light eyes: p¼0.42 at first visit; p¼ 0.49 at fol-
low-up, Mann–Whitney U test). No significant differences in
skin type, natural skin pigmentation measured by reflectance
spectroscopy, self-reported sunburn history, the degree of
chronic sun exposure, or the number of markers of chronic
sun exposure were identified between carriers, non-carriers,
and spouse control subjects.
Development of melanoma in the study population Four
of the 13 mutation carriers developed invasive melanoma,
two of whom were diagnosed during the follow-up interval.
Mutation carriers were stratified into subjects with and
without melanoma. Three of four mutation carriers with me-
lanoma had red hair (p¼0.11, Mann–Whitney U test). Dif-
ferences in other constitutional or environmental factors or
skin pigmentation were not identified. Subjects with me-
lanoma showed a larger mean TNN and TND (at initial ex-
amination and at follow-up) but the differences did not
achieve statistical significance. Three of the four subjects
with melanoma had more than 80 nevi (range 83–97) at the
initial examination. At follow-up, the TNN in these three in-
dividuals was more than 100 (range 108–199). In contrast,
the fourth subject had a non-carrier-like nevus phenotype
with only one nevus at the initial examination and five nevi at
follow-up. Differences in the nevus size distribution (p3
mm, 4–5 mm, and X6 mm) were not identified among mu-
tation carriers with and without melanoma, at either the in-
itial (pX0.15) or follow-up (pX0.33) examinations.
The mean age of the four male subjects with melanoma
was 31 y at the time of diagnosis, as compared with a mean
of 58 y in Caucasian men in Utah (Utah Cancer Registry
data, personal communication, Charles Wiggins, PhD, May
2003). Two of the four participants with melanoma devel-
oped multiple primary melanomas, and one of those also
developed pancreatic adenocarcinoma (Parker et al, 2003).
The subject with the largest TNN and TND developed six
invasive melanomas, five melanoma in situ lesions, and
multiple atypical spindle cell and dysplastic nevi. In sum,
the mutation carrier group developed 11 melanomas and
four of these lesions were diagnosed during the follow-up
interval. One non-carrier subject was discovered to have an
invasive melanoma at age 53 y, during the follow-up inter-
val. This individual had a mutation carrier-like phenotype
with 75 nevi and the largest TND of the non-carriers at
follow-up.
Discussion
A major risk factor for melanoma, regardless of the
CDKN2A mutational status, is the number of nevi present
on the skin (Swerdlow et al, 1986; Bataille et al, 1996, 1998;
Kefford and Mann, 2003). Whereas much is known about
the natural history of nevi during the first two decades of life,
only a few reports of nevus history in healthy adult popu-
lations are available and suggest that: (1) nevi are rare at
birth and begin to develop in early childhood (MacKie et al,
1998; Harrison et al, 2000); (2) nevi peak in number at ap-
proximately 20–40 nevi during the second through fourth
decades of life (Nicholls, 1973; Cooke et al, 1985; MacKie
et al, 1985); and (3) nevi decline substantially to very few by
the eighth decade (Nicholls, 1973; MacKie et al, 1985).
We have thoroughly characterized a large family with a
pathogenic V126D CDKN2A mutation. The V126D CDKN2A
mutation present in this particular melanoma kindred has a
profound effect on nevus development that is exaggerated
over a mean follow-up period of 15 y. Individuals carrying
this mutation, on average, have increased numbers of nevi,
whereas non-carrier and spouse control subjects have de-
creased numbers of nevi over time in a manner similar to
previous population-based studies (Nicholls, 1973; Cooke
et al, 1985; MacKie et al, 1985). Moreover, mutation carriers
had increased numbers of nevi in all size categories over
time, suggesting that these subjects continue to develop
new nevi and that existing nevi increase in size with time.
Unfortunately, the previous body map diagrams were not
sufficiently detailed to allow direct comparison of individual
nevi at the follow-up examination. Cellular and molecular
evidence is accumulating to suggest that CDKN2A is a
prominent regulator of melanocyte senescence (Bennett,
2003). It is possible that regression of nevi in non-carriers
and spouse controls (and lack of regression in carriers with
diminished CDKN2A function) represents a clinical cor-
relate to the cellular senescence function of CDKN2A in
melanocytes.
The identification of an intermediate phenotype in non-
carrier kindred members compared with spouse control
subjects suggests the presence of other nevogenic or
modifier genes that elevate the number of nevi in non-
carriers and may increase the penetrance of nevi and me-
lanomas in mutation carriers. In addition, the degree of
variability in the TNN and TND is striking and shows con-
siderable overlap among the mutation carriers and non-
carriers, also suggesting the presence of a nevogenic
modifier gene(s). Although mutation carrier subjects had
significantly more atypical nevi than the other groups, the
clinical phenotype did not discriminate mutation carriers
from non-carriers, a finding corroborated by others (Bishop
et al, 2000) and illustrated by two participants with ‘‘outlier’’
nevus phenotypes who developed melanoma (one each in
the mutation carrier and non-carrier groups), Thus, among
kindreds that carry CDKN2A mutations, the most reliable
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method of identifying individuals at highest risk is DNA se-
quence analysis of CDKN2A.
Kindred subjects and spouse controls in our study are all
of northern European descent; thus, most phenotypic char-
acteristics among the mutation carriers, non-carriers and
spouse control subjects were similar because they share a
common genetic background. We were unable to identify
significant differences among the three groups for any of the
well-established melanoma risk factors. Therefore, the dif-
ferences in nevus phenotype among the genotypic groups
could not be attributed to known environmental or consti-
tutional factors. It was notable, however, that three of the
four mutation carriers that developed melanoma had red
hair and all of the mutation carriers had light-colored eyes.
Both red hair and light eye color have previously been as-
sociated with increased risk for cutaneous melanoma (Mar-
rett et al, 1992; Bliss et al, 1995) and melanocortin 1
receptor (MC1R) variants (red hair phenotype) are associ-
ated with increased melanoma risk in CDKN2A kindreds
(Box et al, 2001). Our data support the notion that co-
inheritance of additional established risk factors (i.e., red
hair, light eyes, etc.) superimposes further risk upon the
CDKN2A mutation status.
Our study represents a longitudinal evaluation of a well-
characterized melanoma kindred carrying a CDKN2A mu-
tation with respect to the natural history of nevus develop-
ment. The somewhat low rate of recruitment in our study
raises the possibility of self-selection bias for those individ-
uals with large numbers of nevi or a history of melanoma.
Although we are unable to exclude self-selection bias or
assess its impact on our data, the effect is likely to be lim-
ited because the kindred participants were unaware of their
CDKN2A mutation status. Furthermore, the rate of recruit-
ment for kindred members and spouse controls was similar
(45% for kindred members and 56% of spouse control
subjects), despite significant differences in number of nevi.
We have confirmed previously reported findings that mu-
tation carriers develop more nevi than non-carriers or spouse
controls (Cannon-Albright et al, 1994). Furthermore, we have
shown that, over time, mutation carriers continue to develop
nevi, unlike the non-carrier or spouse control subjects. Fur-
ther study is required to determine if non-carrier subjects are
at increased risk of developing melanoma, a likely possibility
given the evidence of an intermediate nevus phenotype in
these subjects and data from the Melanoma Genetics Con-
sortium suggesting a higher incidence of melanoma in non-
carrier members of high-risk pedigrees compared with the
general population (Kefford and Mann, 2003). These data
provide additional support that CDKN2A is important not
only in the development of melanoma, but also in growth
regulation of benign melanocytic lesions. In addition, the ex-
istence of other nevogenic or modifying genes is likely.
Materials and Methods
Recruitment of subjects This study was approved by the Institu-
tional Review Board at the University of Utah. All clinical investiga-
tion was conducted according to Declaration of Helsinki principles.
Sixty-four members of this melanoma kindred and 16 spouse con-
trol subjects were contacted by letter inviting them to participate in a
follow-up study. Phenotypic data regarding these individuals were
not part of the recruitment strategy and were not available to re-
cruitment personnel. Informed consent was obtained from kindred
members agreeing to participate. Twenty-nine kindred members
and nine spouse control subjects were recruited for this study.
Subjects were not aware of their CDKN2A mutation status.
Phenotypic data collection Phenotypic data were obtained from
the following sources: (1) family history and epidemiologic ques-
tionnaires; (2) comprehensive total-body skin examination; and (3)
reflectance spectrophotometry.
History and epidemiology questionnaires All but one of the
participants completed family history and epidemiology question-
naires. Participants self-reported natural hair color, natural eye
color, childhood freckling on a scale of 1–3 (1¼ none, 2¼ few, and
3¼many), and the approximate number of sunburns experienced
during the first, second, and third decades of life (0¼ subject un-
sure, 1¼ zero, 2¼ 1–3, 3¼ 4–10, and 4¼more than 10 sunburns).
Reported melanomas were confirmed through the Utah Cancer
Registry, by obtaining the pathology report, and by review of his-
tologic slides by dermatopathologists (SRF and RMH).
Total body skin examination All participants were examined by
the same dermatologist (LJM) in the late 1980s and in this study.
The dermatologist remained blinded to subject genotype status
and had not examined or followed any subject in clinic in the in-
tervening time period between the initial and follow-up examina-
tions. Both examinations included a comprehensive total body skin
examination in which the location and size of each clinically de-
tectable nevus X2 mm in diameter was recorded on a body map
diagram by the same protocol utilized in the previous study (Meyer
et al, 1992). The number of clinically atypical nevi (defined as hav-
ing one or more atypical clinical features including border irregu-
larity, color asymmetry, presence of multiple colors, diffusion of
pigment, or irregular contour) was recorded (for the follow-up ex-
amination only). In addition, a subjective assessment of overall and
body site-specific chronic sun exposure was made (scale 0–3;
0¼ not detectable, 3¼ severe) based on the presence of actinic
keratoses, solar elastosis, poikiloderma, and solar lentigines. The
Fitzpatrick skin type was also assigned by the examiner.
Reﬂectance spectrophotometry An objective measure of natural
skin pigmentation was determined by reflectance spectrophotom-
etry (Green and Martin, 1990). Skin reflectance between wave-
lengths 450 and 850 nm was measured with a fiberoptic computer-
based visible light spectrophotometer (S2000 Miniature Fiber Optic
Spectrometer, Ocean Optics, Dundedin, Florida) at the inner upper
arm, a sun-protected location. The calculated area under the curve
between 450 and 615 nm was recorded for each subject.
CDKN2A mutational status To verify genotype, DNA was ex-
tracted from peripheral blood leukocytes using a commercial kit
(Gentra Systems, Minneapolis, Minnesota) followed by PCR-based
DNA sequencing. The promoter region and exons 1a–3 of CDKN2A
and exon 1b (ARF) were sequenced on an automated sequencer
(University of Utah Sequencing Core Facility and Yale Diagnostic
Laboratory, New Haven, Connecticut) to exclude the possibility of
other CDKN2A or ARF mutations.
Statistical analysis The TNN was defined as the number of clin-
ically detectable nevi X2 mm in diameter. Lesions o2 mm in di-
ameter were excluded to reduce the possibility of erroneously
including freckles in the TNN (Nicholls, 1973). TND was estimated
by calculating the area of all nevi using the formula Spr2 divided by
the estimated body surface area of the individual, as described
previously (Goldgar et al, 1991; Meyer et al, 1992).
Statistical analysis was performed using Statistica software
(Releases 5.1 and 6.0, StatSoft, Inc). Comparison of medians was
done using the exact Mann–Whitney U test. Multiple regression
analyses were performed to adjust for age and sex, with TNN,
change in number of nevi, TND, or change in TND as the single
dependent variable, and age at initial visit, sex, and carrier status
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as dependent variables. Sex and carrier status were incorporated
through the use of indicator variables.
To compare the rates of nevus formation during two time pe-
riods, two ratios were computed: R1¼ (# nevi at initial visit)/(initial
age), and R2¼ (# nevi at follow-up# nevi at initial visit)/(age at
follow-upage at initial visit). R1 and R2 were compared using the
exact Wilcoxon matched-pair test. For change in TNN, the squared
deviation from the genotypic group mean was computed, and the
variability among the genotypic groups was evaluated by applying
the Kruskal–Wallis ANOVA. All reported p-values are two-tailed.
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